ZNF198-FGFR1 Transforms Ba/F3 Cells to Growth Factor Independence and Results in High Level Tyrosine Phosphorylation of STATS 1 and 5

Neoplasia

Volumn 1, Issue 4, 1999, Pages 349-355

  Smedley, Damian ^a   Demiroglu, Asuman ^b   Abdul Rauf, Munah ^a   Heath, Carol ^b   Cooper, Colin ^a   Shipley, Janet ^a   Cross, Nicholas C P ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

FGFR1; t(8; 13); Tyrosine kinase; ZNF193

Indexed keywords

DNA BINDING PROTEIN; FGFR1 PROTEIN, HUMAN; FGFR1 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GROWTH PROMOTOR; HYBRID PROTEIN; INTERLEUKIN 3; MILK PROTEIN; MYC PROTEIN; PROTEIN TYROSINE KINASE; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; STAT1 PROTEIN, MOUSE; STAT5 PROTEIN; TRANSACTIVATOR PROTEIN; TYROSINE;

ANIMAL; ARTICLE; CELL LINE; CELL STRAIN COS1; CYTOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC RECOMBINATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE; MYELOPROLIFERATIVE DISORDER; PHOSPHORYLATION; PROTEIN SYNTHESIS; SERODIAGNOSIS; SIGNAL TRANSDUCTION; TIME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE; COS CELLS; CYTOPLASM; DNA-BINDING PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; GROWTH SUBSTANCES; HUMANS; INTERLEUKIN-3; MICE; MILK PROTEINS; MYELOPROLIFERATIVE DISORDERS; PHOSPHORYLATION; PRECIPITIN TESTS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TIME FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TYROSINE;

EID: 0033206227     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900035     Document Type: Article

References (38)

1. Macdonald D, Aguiar RCT, Mason PJ, Goldman JM, and Cross NCP (1995). A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia 9, 1628-1630.
2. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DHC, Aguiar RCT, Goncalves C, Hernandez JM, Jennings BA, Goldman JM, and Cross NCP (1998). Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 92, 1735-1742.
3. Smedley D, Hamoudi R, Clark J, Warren W, Abdul Rauf M, Somers G, Venter D, Fagan K, Cooper C, and Shipley J (1998). The t(8;13)-(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum Mol Genet 7, 637-642.
4. Popovici C, Adelaide J, Ollendorff V, Chaffanet M, Guasch G, Jacrot M, Leroux D, Birnbaum D, and Pebusque MJ (1998). Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci USA 95, 5712-5717.
5. Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ, and Fletcher JA (1998). FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/ lymphoma syndrome. Nat Genet 18, 84-87.
6. Chaffanet M, Popovici C, Leroux D, Jacrot M, Adelaide J, Dastugue N, Gregoire MJ, Hagemeijer A, Lafage Pochitaloff M, Birnbaum D, and Pebusque MJ (1998). t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12. Oncogene 16, 945-949.
7. Heisterkamp N, Stam K, Groffen J, de Klein A, and Grosveld G (1985). Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315, 758-761.
8. Shtivelman E, Lifshit, B, Gale RP, and Canaani E (1985). Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315, 550-554.
9. Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F, and Hoglund M (1997). BCR/ABL negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 20, 299-304.
10. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, and Wiedemann LM (1995). The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 55, 34-38.
11. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, and Marynen P (1997). Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90, 2535-2540.
12. Golub TR, Barker GF, Lovett M, and Gilliland DG (1994). Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77, 307-316.
13. Ross TS, Bernard OA, Berger R, and Gilliland DG (1998). Fusion of Huntington interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91, 4419-4426.
14. McLaughlin J, Chianese E, and Witte ON (1987). In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84, 6558-6562.
15. Daley GQ, Van Etten RA, and Baltimore D (1990). Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830.
16. Carroll M, Tomasson MH, Barker GF, Golub TR, and Gilliland DG (1996). The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 93, 14845-14850.
17. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, Van Rompaey L, Van Etten RA, Ilaria R, Marynen P, and Gilliland DG (1998). Transformation of hematopoietic cell lines to growth factor independence and induction of a fatal myelo-and lymphoproliferative disease in mice by retrovirally transduced TEL/ JAK2 genes. EMBO J 17, 5321-5333.
18. Salgia R, Sattler M, Pisick E, Li JL, and Griffin JD (1996). p210BCR/ ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol 24, 310-3.
19. Aster JC, Robertson ES, Hasserjian RP, Turner JR, Kieff E, and Sklar J (1997). Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription. J Biol Chem 272, 11336-11343.
20. Huang J, Mohammadi M, Rodrigues GA, and Schlessinger J (1995). Reduced activation of RAF-1 and MAP kinase by a fibroblast growth factor receptor mutant deficient in stimulation of phosphatidylinositol hydrolysis. J Biol Chem 270, 5065-5072.
21. Hannemann JR, McManus DM, Kabarowski JHS, and Wiedemann LM (1998). Haemopoietic transformation by the TEL/ABL oncogene. Br J Haematol 102, 475-485.
22. Mohammadi M, Honegger AM, Rotin D, Fischer R, Bellot F, Li W, Dionne CA, Jaye M, Rubinstein M, and Schlessinger J (1991). A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (FIg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol 11, 5068-5078.
23. Stachowiak EK, Maher PA, Tucholski J, Mordechai E, Joy A, Moffett J, Coons S, and Stachowiak MK (1997). Growth factor regulation of cell growth and proliferation in the nervous system. A new intracrine nuclear mechanism. Oncogene 14, 2201-2211.
24. McWhirter JR, and Wang JY (1993). An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 12, 1533-1546.
25. Lugo TG, Pendergast AM, Muller AJ, and Witte ON (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082.
26. Mackay JP, and Crossley M. (1998). Zinc fingers are sticking together. Trends in Biochemical Sciences 23, 1-4.
27. Gabrilove JL, White K, Rahman Z, and Wilson EL (1994). Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth. Blood 83, 907-10.
28. Berardi AC, Wang A, Abraham J, and Scadden DT (1995). Basic fibroblast growth factor mediates its effects on committed myeloid progenitors by direct action and has no effect on hematopoietic stem cells. Blood 86 2123-2129.
29. Ratajczak MZ, Ratajczak J, Skorska M, Marlicz W, Calabretta B, Pletcher CH, Moore J, and Gewirtz AM (1996). Effect of basic (FGF-2) and acidic (FGF-1) fibroblast growth factors on early haemopoietic cell development. Br J Haematol 93, 772-782.
30. Kouhara H, Hadari YR, Spivak Kroizman T, Schilling J, Bar Sagi D, Lax I, and Schlessinger J (1997). A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89, 693-702.
31. Hadari YR, Kouhara H, Lax I, and Schlessinger J (1998). Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol Cell Biol 18, 3966-3973.
32. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, and Schlessinger J (1996). Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 16, 977-989.
33. Mohammadi M, Dionne CA, Li W, Li N, Spivak T, Honegger AM, Jaye M, and Schlessinger J (1992). Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature 358, 681-684.
34. Peters KG, Marie J, Wilson E, Ives HE, Escobedo J, Dei Rosario M, Mirda D, and Williams LT (1992). Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature 358, 678-681.
35. Wetzler M, Talpaz M, Van Etten RA, Hirsh Ginsberg C, Beran M, and Kurzrock R (1993). Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 92, 1925-1939.
36. Sawyers CL (1997). Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol 10, 223-231.
37. Shuai K, Halpern J, ten Hoeve J, Rao X, and Sawyers CL (1996). Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13, 247-254.
38. Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA, and Fu XY (1997). Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386, 288-292.